Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer

Brazilian Journal of Medical and Biological Research

Volumn 46, Issue 8, 2013, Pages 650-658

  Sheng, W J ^a   Jiang, H ^a   Wu, D L ^b   Zheng, J H ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Cisplatin; Epithelial ovarian cancer; Nedaplatin; Oxaliplatin; STAT3

Indexed keywords

BETA ACTIN; CISPLATIN; CYCLIN D1; NEDAPLATIN; OXALIPLATIN; PROTEIN BCL XL; STAT3 PROTEIN; SURVIVIN; VASCULOTROPIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; OXAZINES; RATS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XANTHENES;

EID: 84883501545     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20133003     Document Type: Article

References (39)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529, doi: 10.1056/NEJMra041842.
2. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006; 103: 1070-1076, doi: 10.1016/j.ygyno.2006.06.025.
3. Koshiyama M, Kinezaki M, Uchida T, Sumitomo M. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin. Anticancer Res 2005; 25: 4499-4502.
4. Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065-1070, doi: 10.1093/oxfordjournals.annonc. a010500.
5. Ferrandina G, Ludovisi M, De Vincenzo R, Salutari V, Lorusso D, Colangelo M, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol 2007; 18: 1348-1353, doi: 10.1093/annonc/mdm136.
6. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010; 39: 8113-8127, doi: 10.1039/c0dt00292e.
7. Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, et al. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Hum Gene Ther 2012; 23: 32-45, doi:10.1089/hum.2011.101.
8. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006; 12: 5055-5063, doi: 10.1158/1078-0432. CCR-06-0861.
9. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004; 64: 3550-3558, doi:10.1158/0008-5472.CAN-03-3959.
10. Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, Amin HM, Lai R, et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006; 107: 2730-2740, doi: 10.1002/cncr.22293.
11. Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 2012; 31: 2309-2322, doi: 10.1038/onc.2011.409.
12. Kandala PK, Srivastava SK. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3). BMC Med 2012; 10: 9, doi: 10.1186/1741-7015-10-9.
13. Colomiere M, Findlay J, Ackland L, Ahmed N. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin. Int J Biochem Cell Biol 2009; 41: 1034-1045, doi: 10.1016/j.biocel.2008.09.018.
14. Hall J, Guo G, Wray J, Eyres I, Nichols J, Grotewold L, et al. Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. Cell Stem Cell 2009; 5: 597-609, doi: 10.1016/j.stem.2009.11.003.
15. Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H, et al. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci 2010; 101: 2128-2136, doi: 10.1111/j.1349-7006.2010.01652.x.
16. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24: 1053-1065, doi: 10.1038/sj.onc.1208298.
17. Gest C, Mirshahi P, Li H, Pritchard LL, Joimel U, Blot E, et al. Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets. Cancer Lett 2012; 317: 207-217, doi: 10.1016/ j.canlet.2011.11.026.
18. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005; 92: 1149-1158, doi:10.1038/sj.bjc.6602447.
19. Walker SR, Chaudhury M, Nelson EA, Frank DA. Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol 2010; 78: 903-908, doi: 10.1124/ mol.110.066316.
20. L'Esperance S, Bachvarova M, Tetu B, Mes-Masson AM, Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008; 9: 99, doi: 10.1186/1471-2164-9-99.
21. Bates RC, Buret A, van Helden DF, Horton MA, Burns GF. Apoptosis induced by inhibition of intercellular contact. J Cell Biol 1994; 125: 403-415, doi: 10.1083/jcb.125.2.403.
22. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626, doi: 10.1083/jcb.124.4.619.
23. Blazer DG III, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351, doi: 10.1200/JCO.2008.17.5299.
24. Konnikova L, Simeone MC, Kruger MM, Kotecki M, Cochran BH. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 2005; 65: 6516-6520, doi: 10.1158/0008-5472.CAN-05-0924.
25. Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther 2010; 9: 1169-1179, doi:10.1158/1535-7163.MCT-09-1207.
26. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109 (Suppl): S121-S131, doi: 10.1016/S0092-8674(02)00701-8.
27. Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kalai T, et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther 2011; 12: 837-845, doi: 10.4161/cbt.12.9.17713.
28. Haviland R, Eschrich S, Bloom G, Ma Y, Minton S, Jove R, et al. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. PLoS One 2011; 6: e24923, doi: 10.1371/journal.pone.0024923.
29. Huang S, Chen M, Shen Y, Shen W, Guo H, Gao Q, et al. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 2012; 315: 198-205, doi: 10.1016/j.canlet.2011.10.011.
30. Guo Y, Nemeth J, O'Brien C, Susa M, Liu X, Zhang Z, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 2010; 16: 5759-5769, doi: 10.1158/1078-0432.CCR-10-1095.
31. Selvendiran K, Kuppusamy ML, Ahmed S, Bratasz A, Meenakshisundaram G, Rivera BK, et al. Oxygenation inhibits ovarian tumor growth by downregulating STAT3 and cyclin-D1 expressions. Cancer Biol Ther 2010; 10: 386-390, doi: 10.4161/cbt.10.4.12448.
32. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257, doi: 10.1038/35025220.
33. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006; 118: 879-888, doi:10.1002/ijc.21421.
34. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004; 94: 630-635, doi:10.1016/j.ygyno.2004.05.056.
35. Lee JH, Schutte D, Wulf G, Fuzesi L, Radzun HJ, Schweyer S, et al. Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/ Bcl-XL pathway. Hum Mol Genet 2006; 15: 201-211, doi:10.1093/hmg/ddi430.
36. Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 2008; 8: 129, doi: 10.1186/1471-2407-8-129.
37. Asechi H, Hatano E, Nitta T, Tada M, Iwaisako K, Tamaki N, et al. Resistance to cisplatin-induced apoptosis via PI3Kdependent survivin expression in a rat hepatoma cell line. Int J Oncol 2010; 37: 89-96.
38. Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I, Ikeda M, et al. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci 2008; 99: 129-139.
39. Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, et al. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer 2011; 105: 1759-1767, doi: 10.1038/ bjc.2011.449.